Skip to content

US · FLGT · MEDICAL - DIAGNOSTICS & RESEARCH

Fulgent Genetics, Inc. (FLGT) intrinsic value and stock valuation

$24.12as of 2026-11-21 · Mkt cap 526.26M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Fulgent Genetics, Inc. DCF and intrinsic value

InvestorsCraft values FLGT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FLGT’s statements →

Fulgent Genetics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research El Monte, CA 91731 fulgentgenetics.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$322.7M-5.2% 5y CAGRd
20142025
Net income
-$-60.51M
20142025
Free cash flow
-$-124.21M
20142025
Total equity
$1.11B+14.2% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$322.7M$283.5M$289.2M$619M$992.6M
Operating income-$-91.1M-$-73.92M-$-195.53M$178.5M$676M
Net income-$-60.51M-$-42.71M-$-167.82M$143.4M$507.4M
EPSd-$-1.97M-$-1.41M-$-5.64M$4.63M$16.4M
Operating cash flow-$-101.64M$21.1M$27M$253.5M$538.6M
Capital expenditure-$-22.57M-$-40.31M-$-22.21M-$-18.77M-$-23.84M
Free cash flow-$-124.21M-$-19.25M$4.8M$234.8M$514.7M
Total assets$1.21B$1.22B$1.24B$1.39B$1.28B
Total debt$7.68M$8.47M$15.3M$38.9M$21.3M
Net debt-$-42.52M-$-46.68M-$-82.22M-$-40.57M-$-143.61M
Total equity$1.11B$1.13B$1.13B$1.27B$1.17B
Cash and short-term investments$336.1M$258.1M$424.2M$526.2M$450.5M
Income statement
20252024202320222021
Revenue$322.7M$283.5M$289.2M$619M$992.6M
Cost of revenue$191.8M$176.3M$184.8M$252.1M$215.5M
Gross profit$130.9M$107.2M$104.5M$366.9M$777.1M
Research and development expenses$53.9M$48.8M$41.4M$28.9M$24.2M
Selling, general and administrative expenses$160M$124.4M$130.5M$150M$75.2M
Other expenses$8.03M$7.96M$128.1M$9.47M$1.71M
Operating expenses$222M$181.1M$300M$188.4M$101.1M
Cost and expenses$413.8M$357.4M$484.7M$440.4M$316.6M
Interest income$30.9M$31.3M$21.6M$5.62M$1.35M
Interest expense$70K$170K$490K$1.01M$0.00
Depreciation and amortization$24.1M$24.9M$26.1M$32.7M$11M
Ebitda-$-45.83M-$-26.86M-$-147.45M$217.7M$692M
Operating income-$-91.1M-$-73.92M-$-195.53M$178.5M$676M
Total other income/expenses, net$21.1M$22M$21.4M$5.5M$5.08M
Income before tax-$-70.03M-$-51.96M-$-174.09M$184M$681M
Income tax expense-$-8.39M-$-8.14M$1.15M$42.1M$174.8M
Net income-$-60.51M-$-42.71M-$-167.82M$143.4M$507.4M
Weighted average shares outstanding$30.8M$30.2M$29.8M$30.1M$29.4M
Weighted average diluted shares outstanding$30.8M$30.2M$29.8M$31M$31M
Balance sheet
20252024202320222021
Cash and short-term investments$336.1M$258.1M$424.2M$526.2M$450.5M
Net receivables$91.6M$77M$57.5M$75.1M$143.3M
Inventory$10.6M$8.38M$5.83M$4.28M$12.2M
Total current assets$550.5M$353.6M$507.9M$627.9M$612M
Property, plant and equipment, net$112.6M$105.6M$83.5M$81.4M$62.3M
Goodwill and intangible assets$158.4M$157M$165.1M$293.7M$86.8M
Long-term investments$369.3M$570.4M$444M$339M$507M
Total non-current assets$663M$866.4M$727.5M$758.2M$666.8M
Total assets$1.21B$1.22B$1.24B$1.39B$1.28B
Accounts payable$18.7M$18.4M$15.4M$23.1M$20.5M
Short-term debt$1.94M$1.85M$5.14M$26.8M$21.3M
Deferred revenue$31.8M$29.8M$25.6M$14.1M$34.4M
Total current liabilities$85M$72.9M$73M$88.1M$105.3M
Long-term debt$5.74M$6.61M$10.1M$12.2M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$21.8M$17.9M$29M$28.1M$7.53M
Capital lease obligations$5.24M$5.56M$11.1M$14.9M$0.00
Total liabilities$106.8M$90.8M$102M$116.2M$112.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$530M$590.5M$633.2M$801M$657.6M
Accumulated other comprehensive income (loss)$7.51M-$-370K$1.21M-$-20.9M-$-760K
Total equity$1.11B$1.13B$1.13B$1.27B$1.17B
Total investments$655.2M$773.3M$770.7M$785.8M$792.6M
Total debt$7.68M$8.47M$15.3M$38.9M$21.3M
Net debt-$-42.52M-$-46.68M-$-82.22M-$-40.57M-$-143.61M
Cash flow statement
20252024202320222021
Net income-$-61.63M-$-43.82M-$-175.24M$141.9M$506.2M
Depreciation and amortization$24.1M$24.9M$26.1M$32.7M$11M
Stock-based compensation$39.6M$44.5M$42.9M$32.6M$15.9M
Change in working capital-$-117.63M-$-7.24M$2.84M$2M-$-2.68M
Accounts receivable-$-23.25M-$-16.3M$2.39M$68.6M$42.3M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$550K$3.07M-$-6.9M-$-25.34M-$-12.21M
Net cash provided by operating activities-$-101.64M$21.1M$27M$253.5M$538.6M
Investments in property, plant and equipment-$-22.57M-$-40.31M-$-22.21M-$-18.77M-$-23.81M
Acquisitions, net$3.77M$0.00-$-400K-$-182.68M-$-61.87M
Net cash used for investing activities$111.4M-$-58.35M$38.9M-$-261.31M-$-546.55M
Common stock issued$0.00$0.00$0.00$0.00$89.5M
Common stock repurchased-$-13.92M-$-3.12M-$-27.79M-$-76.11M-$-4.16M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-14.79M-$-4.85M-$-47.78M-$-77.14M$85.4M
Net change in cash-$-4.95M-$-42.19M$18M-$-85.39M$77.5M
Cash at end of period$50.3M$55.3M$97.5M$79.5M$164.9M
Operating cash flow-$-101.64M$21.1M$27M$253.5M$538.6M
Capital expenditure-$-22.57M-$-40.31M-$-22.21M-$-18.77M-$-23.84M
Free cash flow-$-124.21M-$-19.25M$4.8M$234.8M$514.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Fulgent Genetics, Inc.

        Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.

        CEO
        Ming Hsieh
        Employees
        1.34K
        Beta
        0.89

        Explore

        Frequently asked questions

        What is the intrinsic value of Fulgent Genetics, Inc. (FLGT)?

        Fulgent Genetics, Inc. (FLGT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is FLGT undervalued?

        FLGT trades at a price of $24.12 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.